Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1988 Oct;79(10):1130–1138. doi: 10.1111/j.1349-7006.1988.tb01536.x

Preparation of a Monoclonal Antibody Specific for 1‐Methyladenosine and Its Application for the Detection of Elevated Levels of 1‐Methyladenosine in Urines from Cancer Patients

Kunihiko Itoh 1, Michinao Mizugaki 1, Nakao Ishida 2
PMCID: PMC5917635  PMID: 3143701

Abstract

A monoclonal antibody specific for a modified nucleoside, 1‐methyladenosine, was prepared and characterized. This antibody, termed AMA‐2, reacts with 1‐methyladenosine and 1‐methyladenine but not with other nucleosides, particularly methylated adenosines other than 1‐methyladenosine and methylated guanosines, tested in this investigation. In our experiments, AMA‐2 was used in an enzyme‐linked immunosorbent assay (ELISA) system for the quantitation of the levels of 1‐methyladenosine in urine. Sensitivity was in the picomole range and accuracy was nearly equal to that of the high‐performance liquid chromatography (HPLC) assay system. Urinary levels of 1‐methyladenosine in healthy donors and patients with various advanced cancers were determined by the inhibition ELISA. The amount of 1‐methyladenosine in urine of 33 healthy donors was 1.91±0.66 nmol/μmol creatinine. In 54% (51/94) of patients, urinary 1‐methyladenosine was elevated above the mean plus 2 standard deviations for the healthy donors (3.23 nmol/μmol creatinine). In patients with leukemia, esophageal cancer, stomach cancer, colon cancer, and bladder cancer, urinary levels of 1‐methyladenosine were significantly elevated. In patients with leukemia, urinary 1‐methyladenosine levels changed almost in parallel with the change in the clinical response during chemotherapy. These results suggest that urinary 1‐methyladenosine might be useful in monitoring the effectiveness of therapy.

Keywords: Modified nucleosides, Anti‐1‐methyladenosine monoclonal antibody, Inhibition ELISA, Urines from cancer patients

Full Text

The Full Text of this article is available as a PDF (452.2 KB).

References

  • 1. ) Hall , R. H. “ The Modified Nucleosides in Nucleic Acids ” ( 1971. ). Columbia University Press; , New York . [Google Scholar]
  • 2. ) Weissman , S.M. , Eisen , A. Z. and Lenrio , M.Pseudouridine metabolism III: studies with isotopically labeled pseudouridine . J. Lab. Clin. Med. , 60 , 40 – 47 ( 1962. ). [PubMed] [Google Scholar]
  • 3. ) Borek , E.The morass of tumor markers . Trends Biochem. Sci. , 10 , 182 – 184 ( 1985. ). [Google Scholar]
  • 4. ) Vold , B. S.Modified nucleosides of ribonucleic acids , In “ Markers of Chemically Induced Cancer ,” ed. Freeman G. and Milman H. A. , pp. 31 – 36 ( 1984. ). Noyes Publications; , New Jersey . [Google Scholar]
  • 5. ) Borek , E. , Balga , B. S. , Gehrke , C. W. , Kuo , K. C. , Belman , S. , Troll , W. and Waalkes , T. P.High turnover rate of transfer RNA in tumor tissue . Cancer Res. , 37 , 3362 – 3366 ( 1977. ). [PubMed] [Google Scholar]
  • 6. ) Davis , G. E. , Suits , R. D. , Kuo , K. C. , Gehrke , C. W. , Waalkes , T. P. and Borek , E.High‐performance liquid chromatographic separation and quantitation of nucleosides in urine and some other biological fluids . Clin. Chem. , 23 , 1427 – 1435 ( 1977. ). [PubMed] [Google Scholar]
  • 7. ) Rasmuson , T. , Bjork , G. R. , Damber , L. , Holm , S. E. , Jacobsson , L. , Jappsson , A. , Littbrand , B. , Stigbrand , T. and Westman , G.Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase, and modified nucleosides as biological markers in malignant lymphomas . Recent Results Cancer Res. , 84 , 331 – 343 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Waalkes , T. P. , Abeloff , M. D. , Ettinger , D. S. , Woo , K. B. , Gehrke , C. W. , Kuo , K. C. and Borek , E.Modified ribonucleosides as biological markers for patients with small cell carcinoma of the lung . Eur. J. Cancer Clin. Oncol. , 18 , 1267 – 1274 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Fishbein , A. , Sharma , O. K. , Selikoff , I. J. and Borek , E.Urinary excretion of modified nucleosides in patients with malignant mesothelioma . Cancer Res. , 43 , 2971 – 2974 ( 1983. ). [PubMed] [Google Scholar]
  • 10. ) Takano , S. , Sami , S. , Majima , T. and Ishida , N.Low molecular weight immunosuppressive factors found in elevated amounts in cancer ascitic fluids of mice 2. 1‐Methyladenosine isolated from cancer ascitic fluids enhances Listeria infection in mice . J. Immunopharmacol. , 8 , 59 – 73 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Gehrke , C. W. , Kuo , K. C. , Waalkes , T. P. and Borek , E.Patterns of urinary excretion of modified nucleosides . Cancer Res. , 39 , 1150 – 1153 ( 1979. ). [PubMed] [Google Scholar]
  • 12. ) Erlanger , B. F. and Beiser , S. M.Antibodies specific for ribonucleosides and ribonucleotides and their reaction with DNA . Proc. Natl. Acad. Sci. USA , 52 , 68 – 74 ( 1964. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Gehrke , C. W. , Kuo , K. C. , Davis , G. E. , Suits , R. D. , Waalkes , T. P. and Borek , E.Quantitative high‐performance liquid chromatography of nucleosides in biological materials . J. Chromatogr. , 150 , 455 – 476 ( 1978. ). [DOI] [PubMed] [Google Scholar]
  • 14. ) Sander , G. , Topp , H. , Wieland , G. , Heller‐Schöch , G. and Schoch , G.Possible use of urinary modified RNA metabolites in the measurement of RNA turnover in the human body . Hum. Nutr. Clin. Nutr. , 40C , 103 – 118 ( 1986. ). [PubMed] [Google Scholar]
  • 15. ) Levine , L. , Van Vunakins , H. and Gallo , R. C.Serologic specificities of methylated base immune system . Biochemistry , 10 , 2009 – 2013 ( 1971. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Vold , B. S. , Keith , D. E. , Jr. and Slavil , M.Urine levels of N‐[9‐(β‐D‐ribofuranosyl)‐purin‐6‐ylacarbamoyl]‐l‐threonine, N6‐(Δ2‐isopentenyl)adenosine, and 2′‐O‐methylguanosine as determined by radioimmunoassay for normal subjects and cancer patients . Cancer Res. , 42 , 5265 – 5269 ( 1982. ). [PubMed] [Google Scholar]
  • 17. ) Vold , B. S. , Kraus , L. E. , Rimer , V. G. and Coombs , R. C.Use of a monoclonal antibody to detect elevated levels of a modified nucleoside, N‐[9‐(β‐d‐ribofuranosyl)purin‐6‐ylcarbamoyl]‐l‐threonine, in the urine of breast cancer patients . Cancer Res. , 46 , 3164 – 3167 ( 1986. ). [PubMed] [Google Scholar]
  • 18. ) Dutta , S. P. , Grossberg , A. , Bhargava , A. K. and Chheda , G. B.Radioimmunoassay for a novel urinary nucleoside, N6‐succinyladenosine . Anticancer Res. , 6 , 135 – 138 ( 1986. ). [PubMed] [Google Scholar]
  • 19. ) Waalkes , T. P. , Abeloff , M. D. , Ettinger , D. S. , Woo , K. B. , Gehrke , C. W. , Kuo , K. C. and Borek , E.Biological markers and small cell lung carcinoma of the lung — a clinical evaluation of urinary ribonucleosides . Cancer , 50 , 2457 – 2464 ( 1982. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Borek , E. , Sharma , O. K. and Waalkes , T. P.New application of urinary nucleoside markers . Recent Results Cancer Res. , 84 , 301 – 316 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Borek , E. , Sharma , O. K. and Brewer , J. I.Urinary nucleic acid breakdown products as markers for trophoblastic diseases . Am. J. Obstet. Gynecol. , 146 , 906 – 910 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Borek , E.Toward a universal tumor marker . Tumor Biol. , 5 , 1 – 14 ( 1984. ). [PubMed] [Google Scholar]
  • 23. ) Krstulovic , A. M. , Hartwick , R. A. and Brown , P. R.High performance liquid chromatographic determination of serum UV profiles of normal subjects and patients with breast cancer and benign fibrocystic changes . Clin. Chim. Acta , 97 , 159 – 170 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 24. ) Tamura , S. , Fujioka , H. , Nakao , T. , Hada , T. and Higashino , K.Serum pseudouridine as a biochemical marker in small cell lung cancer . Cancer Res. , 47 , 6138 – 6141 ( 1987. ). [PubMed] [Google Scholar]
  • 25. ) Salvatore , F. , Colonna , A. , Constanzo , F. , Russo , T. , Esposito , F. and Cimino , F.Modified nucleosides in body fluids of tumor bearing patients . Recent Results Cancer Res. , 84 , 360 – 377 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Salvatore , F. , Russo , T. , Colonna , A. , Cimino , L. , Mazzacca , G. and Cimino , F.Pseudouridine determination in blood serum as tumor marker . Cancer Detect. Prev. , 6 , 531 – 536 ( 1983. ). [PubMed] [Google Scholar]
  • 27. ) Tamura , S. , Amuro , Y. , Nakano , T. , Fujii , J. , Moriwaki , Y. , Yamamoto , T. , Hada , T. and Higashino , K.Urinary excretion of pseudouridine in patients with hepatocellular carcinoma . Cancer , 57 , 1571 – 1575 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 28. ) Tamura , S. , Fujii , J. , Nakano , T. , Hada , T. and Higashino , K.Urinary pseudouridine as a tumor marker in cancer patients with small cell lung cancer . Clin. Chim. Acta , 154 , 125 – 132 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 29. ) Hedelman , D. A. , Grever , M. R. , Miser , J. S. and Trewyn , R. W.Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia . J. Natl. Cancer Inst. , 71 , 269 – 273 ( 1983. ). [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES